Colitis ulcerative+1
Not yet recruitingStudy of risankizumab plus anti‑α4β7 integrin antibody versus each alone in adults with moderately to severely active Crohn’s disease or ulcerative colitis
Study of risankizumab plus anti‑α4β7 integrin antibody versus each alone in adults with moderately to severely active Crohn’s disease or ulcerative colitis
- Disease:Colitis ulcerativeCrohn's disease
- Substances:RisankizumabHumanised IgG1 kappa monoclonal antibody against ALFA4BETA7 integrin
Slovakia- Participants:18–64 years · 65+ years
- Substances:Risankizumab
- Sponsor:AbbVie Deutschland GmbH & Co. KG













